Skip to main content
SpringerLink
Log in

Improvements in anemia management with darbepoetin alfa, a new erythropoiesis stimulating protein

  • Chapter
Renal Anemia

  • 113 Accesses

Abstract

There is a high prevalence of chronic kidney disease (CKD) and associated anemia in the United States (US). The Third National Health and Nutrition Examination Survey of 18, 723 participants estimated that there are as many as 6.2 million people in the US with a serum creatinine (SCr) level of 1.5 mg/dl or above [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jones CA, McQuillan G, Kusek J. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 1998;32:992–9. [Erratum, Am J Kidney Dis. 2000;35:178.]

    Google Scholar 

  2. National Institutes of Health. National Insitutes of Diabetes and Digestive and Kidney Diseases. Healthy people 2010. Chronic Kidney Disease 2000.

    Google Scholar 

  3. Kausz AT, Khan SS, Abichandani R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001; 12:1501–7.

    PubMed  CAS  Google Scholar 

  4. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States, J Am Soc Nephrol. 1999;10:1793–800.

    PubMed  CAS  Google Scholar 

  5. Pereira BJ. Optimization of pre-ESRD care: the key to improved dialysis outcomes. Kidney Int. 2000;57:351–65.

    Article  PubMed  CAS  Google Scholar 

  6. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–85.

    Article  PubMed  CAS  Google Scholar 

  7. Klang B, Bjorvell H, Clyne N. Quality of life in predialytic uremic patients. Qual Life Res. 1996;5:109–16.

    Article  PubMed  CAS  Google Scholar 

  8. Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med. 1979;93:449–58.

    PubMed  CAS  Google Scholar 

  9. Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol 2000;53:S2–8.

    PubMed  CAS  Google Scholar 

  10. Winearls CG, Oliver DO, Peppard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic hemodialysis. Lancet. 1986;2:1175–8.

    Article  PubMed  CAS  Google Scholar 

  11. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and phase II clinical trial. N Engl J Med. 1987; 316:73–8.

    Article  PubMed  CAS  Google Scholar 

  12. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol. 2000; 20:375–81.

    PubMed  CAS  Google Scholar 

  13. Lin F-K, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985;82:7580–4.

    Article  PubMed  CAS  Google Scholar 

  14. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989;35:134–48.

    Article  PubMed  CAS  Google Scholar 

  15. Sundal E, Kaeser U. Correction of anemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year’s treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplantation. 1989;4:979–87.

    CAS  Google Scholar 

  16. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double blind placebo-controlled study. Ann Intern Med. 1989;110:108–14.

    Article  PubMed  CAS  Google Scholar 

  17. Revicki D, Brown R. Health related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic kidney disease patients. Am J Kidney Dis. 1995;25:548–54.

    Article  PubMed  CAS  Google Scholar 

  18. Moreno F, Lopez Gomez JM, Sanz-Guajardo D, Jofre R, Valderrabano F. Quality of life in dialysis patients. A Spanish multicentre study. Spanish Cooperative Renal Patients Quality of Life Study Group. Nephrol Dial Transplantation. 1996;11: 125–9.

    Article  Google Scholar 

  19. Drueke T, Eckardt K, Frei U, et al. Does early anemia correction prevent complications of chronic renal failure? Clin Nephrol. 1999;51:1–11.

    PubMed  CAS  Google Scholar 

  20. Egrie J, Eschbach JW, McGuire T, et al. Pharmacokinetics of recombinant human erythropoietin administrered in hemodialysis patients. Kidney Int. 1988;33:262.

    Google Scholar 

  21. Kampf D, Kahl A, Passlick J, et al. Single-dose kinetics of recombinant human erythropoietin after intravenous subcutaneous and intraperitoneal administration. Preliminary results. Contrib Nephrol. 1989;76:106–11.

    PubMed  CAS  Google Scholar 

  22. Amgen Inc. Epogen package insert. Thousand Oaks, CA, USA; 2000.

    Google Scholar 

  23. Eschbach J, De Oreo P, Adamson J, et al. RHuEPO clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997;30: S192–240.

    Google Scholar 

  24. NKF-DOQI. NKF DOQI clinical practice guidelines for the treatment of chronic kidney failure. Am J Kidney Dis. 1997;30:S192–240.

    Google Scholar 

  25. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens. 1990;3:947–55.

    PubMed  CAS  Google Scholar 

  26. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33:821–8.

    Article  PubMed  CAS  Google Scholar 

  27. Bahlmann J, Schoter KH, Scigalla P, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol. 1991;88:90–106.

    PubMed  CAS  Google Scholar 

  28. Klinkmann H, Wieczorek L, Scigalla P. Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study. Artif Organs. 1993;17:219–25.

    Article  PubMed  CAS  Google Scholar 

  29. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405–16.

    PubMed  CAS  Google Scholar 

  30. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84(supplement 1):3–10.

    Article  PubMed  CAS  Google Scholar 

  31. Egrie J, Browne J. Development and characterization of novel erythropoiesis stimualting protein (NESP). Nephrol Dial Transplantation. 2001;16(supplement 3):313.

    Article  Google Scholar 

  32. Elliott SG, Lorenzini T, Strickland E, Delorme E, Egrie JC. Rational design of novel erythropoiesis stimulating protein (ARANESP): a super-sialylated molecule with increased biological activity. Blood. 2000;96:82a [abstract 352].

    Google Scholar 

  33. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392–5.

    PubMed  CAS  Google Scholar 

  34. Allon M, Kleinman K, Walczyk M, et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time- and dose-linear. Presented at the 33rd Annual Meeting and Exposition of the American Society of Nephrology, Toronto, Canada, 2000.

    Google Scholar 

  35. Graf H, Lacombe J-L, Braun J, Gomes da Costa AA. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients. Presented at the 33rd Annual Meeting and Exposition of the American Society of Nephrology, Toronto, Canada, 2000.

    Google Scholar 

  36. Lerner GR, Kale AS, Warady BA, et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in pediatric patients with chronic renal failure (CRF) or end-stage renal disease. Presented at the 33 rd Annual Meeting and Exposition of the American Society of Nephrology, Toronto, Canada, 2000.

    Google Scholar 

  37. Evans JH, Brocklebank JT, Bowmer CJ, Ng PC. Pharmacokinetics of recombinant human erythropoietin in children with renal failure. Nephrol Dial Transplantation. 1991;6:709–14.

    Article  CAS  Google Scholar 

  38. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001;60:741–7.

    Article  PubMed  CAS  Google Scholar 

  39. Suranyi M, Jackson L, Lubina J, McDermott-Vitak AD. Novel erythropoiesis stimulating protein (NESP) administered once every other week corrects anemia in patients with chronic renal insufficiency. Presented at the National Kidney Foundation Annual Meeting, San Francisco, CA, USA, 2001.

    Google Scholar 

  40. Walker R, Locatelli F, Olivares J, Wilkie M, European/Australian NESP Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia in patients with chronic renal insufficiency (CRI) when administered at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Presented at the 10th Annual National Kidney Foundation Clinical Nephrology Meeting, Orlando, FL, USA, 2001.

    Google Scholar 

  41. Macdougall IC. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia. J Am Soc Nephrol. 1998;9:258a-9a [abstract A1317].

    Google Scholar 

  42. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplantation. 2001;16:14–21.

    Article  CAS  Google Scholar 

  43. Nissenson AR, Swan SK, Lindberg JS, et al. Novel erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r-HuEPO when administered once-weekly. Presented at the 33rd Annual Meeting and Exposition of the American Society of Nephrology, Toronto, Canada, 2000.

    Google Scholar 

  44. Vanrenterghem Y, Barany P, Mann J. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week. J Am Soc Nephrol. 1999;10:270A [abstract A1365].

    Google Scholar 

  45. Vanrenterghem Y, Jadoul M, Foret M, Walker R, European/Australian Study Group. Novel erythropoiesis stimulating protein (NESP) administered once every 3 weeks by the intravenous or subcutaneous route maintains hemoglobin (Hb) in dialysis patients. Presented at the ASN/ISN World Congress of Nephrology, San Francisco CA, USA, 2001.

    Google Scholar 

  46. Amgen Inc. Aranesp™ package insert. Thousand Oaks, CA, USA; 2001.

    Google Scholar 

  47. Amgen Inc. Integrated summary of safety. Data on file.

    Google Scholar 

  48. United States Renal Data System. USRDS 1999 Annual Report. National Institute of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 1999.

    Google Scholar 

Download references

Authors
  1. Jill S. Lindberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Inpatient Dialysis Services, SUNY Downstate Medical Center, Brooklyn, New York, USA

    Onyekachi Ifudu (Associate Professor of Medicine, Director) (Associate Professor of Medicine, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Lindberg, J.S. (2002). Improvements in anemia management with darbepoetin alfa, a new erythropoiesis stimulating protein. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-015-9998-6_6

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-6045-7

  • Online ISBN: 978-94-015-9998-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation